Meningioma

P=N/A, N=27, Recruiting, Peking University Third Hospital

Germ cell tumors can present as extra-axial dura-based lesions and should be suspected in young patients with imaging showing lesions with cystic or hemorrhagic components. Pulmonary metastases are infrequent but may be present. For successful treatment, chemotherapy and radiation therapy should always be considered. https://thejns.org/doi/10.3171/CASE25855.

These results highlight limitations of morphology-based classification and emphasize the value of integrated molecular diagnostics in distinguishing these tumors from conventional high-grade meningiomas. Given their sarcoma-like behavior despite a meningioma ancestry, these tumors may not be adequately captured by current meningioma grading schemes.

P2, N=42, Recruiting, Mayo Clinic | Trial completion date: Jan 2031 --> Mar 2032 | Trial primary completion date: Jul 2026 --> Sep 2027

P=N/A, N=150, The Second Affiliated Hospital of Hainan Medical University; The Second Affiliated Hospital of Hainan Medical University

P=N/A, N=84, Completed, Centre Leon Berard | Recruiting --> Completed

Long-term DMPA use is associated with a distinct pattern of multiple, bone-invasive, PR-positive meningiomas. Based on established patterns with other progestins, drug discontinuation and observation before surgical intervention should be considered for asymptomatic lesions, although prospective validation is warranted.

Moreover, the GBM tumor microenvironment (TME) is enriched in arachidonic acid (AA)-derived cyclooxygenase (COX) products prostaglandins (PG) E2 and F2α in combination with enhanced CD24 expression. By our comparative approach, the data hint toward a pro-tumorigenic Siglec10+CX3CR1+ macrophage population depending on the characteristic tumor microenvironment (TME) of highly malignant GBMs.

P2, N=30, Not yet recruiting, Jazz Pharmaceuticals

Overall, we present a molecular targeting strategy for meningiomas that could pave the way for less invasive clinical management of these tumours and, as a result, help reduce patient mortality and morbidity. Metformin and sulforaphane both have FDA and EU pharmaceutical approval and thus could be repurposed promptly to establish a new meningioma therapy regimen.

P1/2, N=25, Recruiting, Fundación de investigación HM | Phase classification: P2 --> P1/2

Despite these advances, challenges remain, particularly in the standardization of classification systems, development of predictive biomarkers and optimization of trial designs. In this comprehensive, state-of-the-art Review we provide an integrated roadmap for meningioma care as well as a framework for ongoing and future research in this field.